Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (621)	10/8/2006 3:16:50 PM
From: nigel bates	Respond to of 625

Cambridge Antibody Technology Announces Acquisition Of Oncology Product Candidate From Enzon Release Date: 27 July Cambridge, UK… Cambridge Antibody Technology (CAT) announces the acquisition of product candidate SS1P (renamed CAT-5001) from Enzon Pharmaceuticals, Inc., based in Bridgewater, New Jersey in May 2006. The safety profile of CAT-5001 has been characterised in two Phase I clinical trials in patients with mesothelioma, ovarian and pancreatic cancer. CAT intends to conduct further pre-clinical studies and to initiate a clinical study in early 2007 exploring dosing of CAT-5001 in combination with cytotoxic chemotherapy. CAT-5001 was discovered and initially developed by the National Cancer Institute (NCI), which is part of the US National Institutes of Health (NIH). The programme was licensed to Enzon and that licence has now been assigned to CAT. Under the original licence agreement with the NIH, CAT will have rights to a portfolio of intellectual property associated with the programmes and will pay future royalties to NIH. CAT-5001 is an immunotoxin fusion protein between a murine anti-mesothelin dsFv and the Pseudomonas exotoxin PE38. Mesothelin is a glycosylphosphatidylinositol-linked cell surface glycoprotein present on normal mesothelial cells that is overexpressed in numerous cancers including mesothelioma, ovarian cancer and pancreatic cancer. The immunotoxin CAT-5001, like CAT-3888 and CAT-8015, comprises a disulphide-linked Fv antibody fragment (dsFv) that targets the antigen, fused with a specifically engineered toxin molecule that minimises non-targeted toxicity, resulting in a highly specific, highly potent therapeutic molecule. The molecule acts by releasing the toxin intracellularly after the whole immunotoxin has been internalised. Dr Patrick Round, Senior Vice President Development at CAT, commented: "Following the acquisition of CAT-3888 and CAT-8015 in October last year, the acquisition of CAT-5001 is a further step in enhancing our pipeline and presence in oncology and we are delighted to have broadened our relationship with Dr Ira Pastan and his team at the NCI."